{"id":"dexamethasone-intraocular-suspension-9","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Cataract formation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation or discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene production, and suppressing immune cell infiltration and cytokine release. The intraocular suspension formulation delivers the drug directly to ocular tissues, providing sustained local anti-inflammatory effects while minimizing systemic exposure.","oneSentence":"Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:44:26.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammation and pain following ocular surgery"},{"name":"Uveitis and other intraocular inflammatory conditions"},{"name":"Macular edema"}]},"trialDetails":[{"nctId":"NCT04184999","phase":"PHASE4","title":"Effect of Intraoperative Dexamethasone on Post-op Dry Eye","status":"COMPLETED","sponsor":"SR Cornea Consultants","startDate":"2019-08-10","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT04316936","phase":"PHASE4","title":"Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery","status":"COMPLETED","sponsor":"Silverstein Eye Centers","startDate":"2019-12-10","conditions":"Cataract Surgery","enrollment":15},{"nctId":"NCT04290676","phase":"","title":"DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2019-11-13","conditions":"Cataract","enrollment":527}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dexycu"],"phase":"marketed","status":"active","brandName":"dexamethasone intraocular suspension, 9%","genericName":"dexamethasone intraocular suspension, 9%","companyName":"SR Cornea Consultants","companyId":"sr-cornea-consultants","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammation and pain following ocular surgery, Uveitis and other intraocular inflammatory conditions, Macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}